Lecap Asset Management Ltd. Invests $493,000 in Hologic, Inc. (NASDAQ:HOLX)

Lecap Asset Management Ltd. purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,052 shares of the medical equipment provider’s stock, valued at approximately $493,000.

Several other hedge funds have also recently bought and sold shares of the company. Signaturefd LLC lifted its position in Hologic by 13.3% in the 3rd quarter. Signaturefd LLC now owns 2,186 shares of the medical equipment provider’s stock valued at $178,000 after purchasing an additional 257 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Hologic by 2.4% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 7,388 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 173 shares during the last quarter. Everence Capital Management Inc. acquired a new position in shares of Hologic in the 3rd quarter worth approximately $389,000. Prentiss Smith & Co. Inc. boosted its holdings in shares of Hologic by 0.3% in the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after buying an additional 130 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Hologic by 18.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 297,229 shares of the medical equipment provider’s stock worth $24,212,000 after buying an additional 45,360 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a report on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Mizuho raised their target price on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Finally, Evercore ISI raised their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $87.50.

Hologic Price Performance

NASDAQ HOLX opened at $80.91 on Friday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $18.88 billion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98. The company has a 50 day moving average price of $80.94 and a two-hundred day moving average price of $77.84. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.93 earnings per share. As a group, equities analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.